This study is in progress, not accepting new patients
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Irvine UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by Edward Garon (ucla)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Edward Garon (ucla)
Professor, Medicine. Authored (or co-authored) 196 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Links
- Trial Awareness and Transparency website
- ID
- NCT03631706
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 304 people participating
- Last Updated